

## HR 8399

### End Taxpayer Subsidies for Drug Ads Act

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Taxation

**Introduced:** Sep 25, 2020

**Current Status:** Referred to the House Committee on Ways and Means.

**Latest Action:** Referred to the House Committee on Ways and Means. (Sep 25, 2020)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/8399>

### Sponsor

**Name:** Rep. Finkenauer, Abby [D-IA-1]

**Party:** Democratic • **State:** IA • **Chamber:** House

### Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Slotkin, Elissa [D-MI-8]	D · MI		Sep 25, 2020
Rep. Trone, David J. [D-MD-6]	D · MD		Dec 2, 2020

### Committee Activity

Committee	Chamber	Activity	Date
Ways and Means Committee	House	Referred To	Sep 25, 2020

### Subjects & Policy Tags

#### Policy Area:

Taxation

### Related Bills

Bill	Relationship	Last Action
116 S 1801	Related bill	Jun 12, 2019: Read twice and referred to the Committee on Finance.
116 S 73	Identical bill	Jan 10, 2019: Read twice and referred to the Committee on Finance.

### Summary (as of Sep 25, 2020)

### End Taxpayer Subsidies for Drug Ads Act

This bill prohibits tax deductions for expenses relating to direct-to-consumer advertising of prescription drugs.

*Direct-to-consumer advertising* is any dissemination, by or on behalf of a sponsor of a prescription drug product, of an advertisement that is (1) in regard to the drug product, and (2) primarily targeted to the general public.

## **Actions Timeline**

---

- **Sep 25, 2020:** Introduced in House
- **Sep 25, 2020:** Referred to the House Committee on Ways and Means.